西那卡塞治疗血透患者继发性甲状旁腺功能亢进的观察

Observation of Cinacalcet in the Treatment of Hemodialysis Patients with Secondary Hyperparathyroidism

目的:观察西那卡塞治疗血透患者继发性甲状旁腺功能亢进的疗效与安全性。方法:30例血透合并继发性甲状旁腺功能亢进的患者随机分为对照组与观察组,对照组予骨化三醇治疗,观察组同时加用西那卡塞,观察比较两组治疗效果。结果:治疗后,两组患者的血清磷、i PTH较治疗前均显著下降。对照组的血钙较治疗前显著升高,观察组患者的血清磷、i PTH下降幅度显著高于对照组,差异均有统计学意义(P<0.05)。观察组治疗有效率92.9%,高于对照组的71.4%,差异均有统计学意义(P<0.05)。观察组不良反应发生率26.7%,与对照组的20.0%比较,差异无统计学意义(P>0.05)。结论:血透患者合并继发性甲状旁腺功能亢进,联用骨化三醇与西那卡塞治疗,效果确切,安全性良好。

Objective：To study the effect and safety of Cinacalcet in hemodialysis patients with secondary hyperparathyroidism（SHPT）.Method：30 hemodialysis patients with SHPT were randomly divided into observation group and control group.Each group was given Calcitriol,besids,the observation group was extra given Cinacalcet.The effect of the two groups were observed.Result：After treatment,in each group,the level of phosphor and i PTH significantly declined.In control group,the calcium level increased.The levels of phosphor and i PTH in the observation group were lower than those in the control group,the differences were statistically significant（P0.05）.The effective rate of the observation group was 92.9%,significantly higher than 71.4% of the control group,the difference was statistically significant（P0.05）.The adverse reaction rate of the observation group was 26.7%,while the adverse reaction rate of the observation group was 20.0%.There was not statistically significant difference between the two groups（P0.05）.Conclusion：For hemodialysis patients with SHPT,Cinacalcet combined with Calcitriol can increase effective rate and has high safety.